TG Therapeutics, Inc. (TGTX): a likely value trap?

Avoid — the crash came from margins collapsing (R&D nearly tripled, operating margin fell from ~25% to ~9%), not just noise.

⚠ TRAP Fundamentals76/100

Fell 11% in 1 trading day(s) — now $46.17

Why TGTX dropped

TGTX reported Q2 2026 earnings on Aug 3 with revenue beating estimates and BRIUMVI sales up 64%, but non-GAAP EPS missed badly and guidance, while raised, came in below what analysts expected — investors sold hard because spending is outrunning growth.

Fwd P/E 14.7Op margin 17.0%Rev growth 69.6%Debt/equity 129.2%Analyst upside 48.5%

How this scored 76/100

✅ Passes all 4 hard checks — profitable, cash-generative, and financially survivable.

✅ Makes money Net profit margin 66.0%

✅ Generates cash Free cash flow $-30M

✅ Not drowning in debt Debt/equity 129.2% (limit 200%)

✅ Can pay its bills Current ratio 5.8 (needs 1+)

Bar length shows how much each metric is worth — a 10-point metric is twice as wide as a 5-point one. Hover any row for what it means.

Profitability Does it actually make money? 22/25

Operating margin 17.0% 6/9

Net profit margin 66.0% 8/8

Return on equity 112.6% 8/8

Growth Is it getting bigger, or dying? 24/25

Revenue growth 69.6% 9/9

Earnings growth 300.0% 8/8

Expected profit change 24.0% 7/8

Value Is it cheap right now? 18/25

Forward P/E 14.7 8/10

PEG ratio 1.6 4/8

Analyst target upside 48.5% 6/7

Balance sheet Will it survive? 12/25

Debt / equity 129.2% 4/10

Current ratio 5.8 8/8

Free cash flow $-30M 0/7

🔒 Read the full AI analysis

Create a free account to unlock the bull case and the risks for TGTX — plus today's other picks.

Analysis generated by SmartStonks's AI from public fundamentals and news, first flagged 2026-08-04. Research only — not financial advice.